However, PRAME activation directly correlates with adverse clinical outcomes in several cancer types and is thought to contribute to tumorigenesis through inhibition of the retinoic-acid pathways for growth arrest and apoptosis (13, 14). The gene discussed is PRAME; the disease is cancer.